^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    PIK3CA expression

    i
    Other names: PIK3CA, Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha, Phosphoinositide-3-kinase, catalytic, alpha polypeptide, Serine/threonine protein kinase PIK3CA, PtdIns-3-kinase subunit P110-alpha, PI3K-alpha, Phosphatidylinositol-4,5-bisphosphate 3-kinase 110 KDa catalytic subunit alpha, Phosphatidylinositol 3-kinase, Catalytic, 110-KD, alpha, PI3-kinase P110 subunit alpha, PI3-kinase subunit alpha, PtdIns-3-kinase subunit alpha, PI3Kalpha, P110alpha, PI3K
    Entrez ID:
    5290
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    11ms
    Potential Contribution of Epithelial Growth Factor Receptor to PI3K/AKT Pathway Dysregulation in Canine Soft Tissue Sarcoma. (PubMed, In Vivo)
    EGFR over-expression, rather than PTEN loss or PIK3CA mutations, may contribute to PI3K/AKT pathway dysregulation in canine STS. Further studies with larger sample sizes and additional validation techniques are necessary to confirm these findings.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PTEN (Phosphatase and tensin homolog)
    |
    EGFR mutation • PIK3CA mutation • EGFR expression • PTEN expression • EGFR positive • EGFR mutation + PIK3CA mutation • PIK3CA expression • PIK3CA overexpression
    12ms
    Construction and validation of immunogenic cell death-related molecular clusters, signature, and immune landscape in pancreatic cancer. (PubMed, Clin Exp Med)
    There were disparities in survival time and tumor immune microenvironment (TIME) between two ICD gene clusters. Additionally, we developed an ICD-related risk model that was validated as an independent prognostic indicator for patients with PC.
    Journal • Tumor mutational burden
    |
    PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • TMB (Tumor Mutational Burden) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • CASP1 (Caspase 1)
    |
    PIK3CA expression
    12ms
    MiR-592 Attenuates Tamoxifen Resistance in Breast Cancer Through PIK3CA-Mediated PI3K/AKT/mTOR Signaling Pathway. (PubMed, Appl Biochem Biotechnol)
    PIK3CA overexpression partially reversed these reductions. In conclusion, our study demonstrates that miR-592 attenuates TAM resistance by inhibiting the PIK3CA-driven PI3K/AKT/mTOR signaling pathway, representing a promising strategy to address chemoresistance in BC.
    Journal
    |
    PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • CDH1 (Cadherin 1) • CASP3 (Caspase 3)
    |
    CDH1 expression • PIK3CA expression • PIK3CA overexpression
    |
    tamoxifen
    1year
    miR-29a Downregulates PIK3CA Expression and Inhibits Cervical Cancer Cell Dynamics: A Comparative Clinical Analysis. (PubMed, Curr Issues Mol Biol)
    These findings indicate that miR-29a can slow the progression of cervical cancer by targeting PIK3CA and potentially aid in its treatment. miR-29a shows promise as a therapeutic agent for inhibiting oncogene expression and controlling cervical cancer progression, especially in advanced-stage cases.
    Journal
    |
    PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • MIR29A (MicroRNA 29a)
    |
    PIK3CA expression • PIK3CA overexpression
    1year
    Vertical inhibition of p110α/AKT and N-cadherin enhances treatment efficacy in PIK3CA-aberrated ovarian cancer cells. (PubMed, Mol Oncol)
    Importantly, co-targeting N-cadherin and p110α/AKT caused additive reduction in cell migration in vitro and metastases formation in vivo. Together, this study reveals the molecular pathways driven by the PIK3CA aberrations and the exploitable vulnerabilities in PIK3CA-aberrated serous ovarian cancer cells.
    Journal
    |
    PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • YAP1 (Yes associated protein 1) • RAC1 (Rac Family Small GTPase 1) • CDH2 (Cadherin 2) • MAPK3 (Mitogen-Activated Protein Kinase 3)
    |
    PIK3CA mutation • PIK3CA E545K • PIK3CA amplification • PIK3CA E545 • PIK3CA expression • AKT1 amplification • PIK3CA overexpression
    1year
    Gene expression profiling of brain metastases and matched primary breast tumours with focus on the immune system and tumour microenvironment (SABCS 2024)
    We found a downregulation of GE signatures related to the immune system and tumour ME in BM compared with PT. This was validated by the lower levels of TILs, CD4+ and CD8+ T cells in BM. The lower immunogenicity of BM may partly explain the reduced effect by immunotherapy intracranially.
    Gene expression profiling • PD(L)-1 Biomarker • BRCA Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • IFNG (Interferon, gamma) • CD276 (CD276 Molecule) • BRCA (Breast cancer early onset) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • IDO1 (Indoleamine 2,3-dioxygenase 1) • CD4 (CD4 Molecule) • SOX2 • CD68 (CD68 Molecule) • TGFB1 (Transforming Growth Factor Beta 1) • FOXP3 (Forkhead Box P3)
    |
    TP53 mutation • PIK3CA mutation • TP53 wild-type • PIK3CA expression • CD4 expression
    |
    nCounter® Breast Cancer 360™ Panel
    1year
    Apolipoprotein-B mRNA-editing complex 3B could be a new potential therapeutic target in endometriosis. (PubMed, Sci Rep)
    Cell migration: mock: p = 0.004, and control siRNA: p = 0.014). In conclusion, this study suggests that APOBEC3B may be a new potential therapeutic target for endometriosis.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • HIF1A (Hypoxia inducible factor 1, alpha subunit) • CASP8 (Caspase 8) • APOBEC3B (Apolipoprotein B MRNA Editing Enzyme Catalytic Subunit 3B) • APOB (Apolipoprotein B)
    |
    PIK3CA expression • HIF1A expression
    1year
    Association Between Recurrence of High-grade Squamous Intraepithelial Lesions of the Uterine Cervix and p16, C-myc and PIK3CA Proteins-A Single-center Retrospective Study. (PubMed, Cell Biochem Biophys)
    Meanwhile, a prediction model F was constructed based on binary logistic regression analysis data with good fit, and through ROC curve analysis. It was found that p16, C-myc, PIK3CA, and logistic model F can effectively predict HPV16/18 (+), with model F having the best diagnostic performance.
    Retrospective data • Journal
    |
    PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • MYC (V-myc avian myelocytomatosis viral oncogene homolog)
    |
    MYC expression • PIK3CA expression
    1year
    The potential of retinoic acid receptors as prognostic biomarkers and therapeutic targets in gastric cancer. (PubMed, Front Oncol)
    In gastric cancer, high expression levels of RARα/RARβ/RARγ/RXRβ transcripts are associated with poor clinical and molecular characteristics as well as with reduced overall-survival. Our data are consistent with the idea that RARα, RARβ, RARγ and RXRβ represent potential prognostic markers and therapeutic targets of gastric cancer.
    Journal
    |
    TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • RARA (Retinoic Acid Receptor Alpha)
    |
    TP53 expression • PIK3CA expression
    over1year
    Research of the unrecognised functions of miR-375 in prostate cancer cells. (PubMed, Cell Mol Biol (Noisy-le-grand))
    In conclusion, miR-375 has anti-proliferative and cell migration inhibitory effects in prostate cancer. However, studies demonstrate that miR-375 may have tumor suppressor and oncogenic effects when considering cell molecular differences.
    Journal
    |
    PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • TSC1 (TSC complex subunit 1) • MIR375 (MicroRNA 375)
    |
    PIK3CA expression
    over1year
    In Silico and In Vitro Study of Isoquercitrin against Kidney Cancer and Inflammation by Triggering Potential Gene Targets. (PubMed, Curr Issues Mol Biol)
    Lastly, the RT-PCR and qRT-PCR findings showed a significant decrease in PTGS2, PIK3CA, and IGF1R gene expression, except for IL6 expression, following dose-dependent treatments with IQ. Thus, we can conclude that isoquercitrin inhibits the expression of PTGS2, PIK3CA, and IGF1R gene targets, which in turn controls kidney cancer and inflammation.
    Preclinical • Journal
    |
    PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • IL6 (Interleukin 6) • IGF1R (Insulin-like growth factor 1 receptor) • PTGS2 (Prostaglandin-Endoperoxide Synthase 2) • PACERR (PTGS2 Antisense NFKB1 Complex-Mediated Expression Regulator RNA)
    |
    PIK3CA expression • PTGS2 expression • IL6 expression
    over1year
    Anticancer potential of grifolin in lung cancer treatment through PI3K/AKT pathway inhibition. (PubMed, Heliyon)
    These anticancer effects were abolished by 740Y-P. Grifolin regulates the PI3K/AKT pathway, thus inhibiting lung cancer progression.
    Journal
    |
    PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • CCND1 (Cyclin D1) • CDK4 (Cyclin-dependent kinase 4) • CDK6 (Cyclin-dependent kinase 6)
    |
    CCND1 expression • PIK3CA expression